Clinical Trial Update: Lu-177 PSMA Treatment in Cell Renal Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Lu-177 PSMA therapy for metastatic renal cell carcinoma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Lu-177 PSMA (Lutetium-177-labeled PSMA ligand)

Snippet

Sponsor: Ankara University | Conditions: Metastatic Renal Cancer | Phase 3 | Status: NOT_YET_RECRUITING